PMID: 9435869Jan 22, 1998Paper

Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody

Cancer Immunology, Immunotherapy : CII
C RennerM Pfreundschuh

Abstract

A group of 15 patients with refractory Hodgkin's disease were treated in a phase I/II trial with the natural-killer (NK)-cell-activating bispecific monoclonal antibody HRS-3/A9, which is directed against the Fc gamma receptor III (CD16 antigen) and the Hodgkin's associated CD30 antigen. The antibody was given four times every 3-4 days, starting with 1 mg/m2. The treatment was well tolerated and the maximum tolerated dose was not reached at 64 mg/m2. Side-effects were rare and consisted of fever, pain in involved lymph nodes and a maculopapulous rash. Nine patients developed human anti-(mouse immunoglobulin) antibodies. One complete and one partial remission (lasting 5 and 3 months, respectively), three minor responses (1 to 11+ months), and one mixed response were achieved. There was no clear-cut dose side-effect or dose/response correlation. NK cell activity increased in most of the patients treated with 4 mg/m2 or higher doses but lasted no longer than 6 weeks after therapy. Our results encourage further clinical trials with this novel immunotherapeutic approach and emphasize the necessity to reduce the immunogenicity of the antibody to allow retreatment of responding patients.

Citations

Jul 10, 1999·Current Opinion in Hematology·R G Bociek, J O Armitage
Jan 19, 2013·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Philippe Fournier, Volker Schirrmacher
May 22, 2020·Journal of Drug Targeting·Vala KafilYadollah Omidi
Dec 22, 1999·The Tohoku Journal of Experimental Medicine·T KudoS Matsuno
Apr 18, 2009·Leukemia & Lymphoma·Tanya M Wildes, Nancy L Bartlett
Jun 20, 2018·Frontiers in Oncology·Christoph Renner, Frank Stenner
Jul 1, 2010·Expert Review of Clinical Pharmacology·Jijie Gu, Tariq Ghayur

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.